Long­time R&D chief Bischof­berg­er leaves Gilead; No­var­tis op­er­a­tions chief heads out; Astel­las taps Bar­ret­to-Ko to run Amer­i­c­as op­er­a­tions

→ Af­ter a stretch of close to 30 years at Gilead $GILD, long­time R&D chief Nor­bert Bischof­berg­er is leav­ing the com­pa­ny. He’ll be step­ping out at the end of April, the lat­est in a whirl­wind se­ries of changes among the top sci­en­tists in bio­phar­ma. Tak­ing his place will be John McHutchi­son, the cur­rent EVP of clin­i­cal re­search at Gilead. An­drew Cheng is step­ping up as chief med­ical of­fi­cer. Both will re­port di­rect­ly to CEO John Mil­li­gan. The change up comes af­ter a stretch of tu­mul­tuous in­no­va­tion at Gilead; but Bischof­berg­er, who helped ush­er out 25 com­pounds at Gilead, will have no trou­ble mov­ing along in this boom­ing biotech in­dus­try what­ev­er he de­cides to do next.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER